Mergen last week became the latest player in the microarray industry to settle litigation with Oxford Gene Technology, and the firm wasted no time in trying to drum up business by offering an OEM service for DNA arrays.

The dispute dates back to December 2002, when OGT filed suit against several firms, including Mergen, for patent infringement. Like the other firms, Mergen filed a countersuit but also entered into discussions with OGT to settle out of court.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In an editorial, officials from scientific societies in the US and China call for the international community to develop criteria and standards for human germline editing.

The Washington Post reports on a Federal Bureau of Investigation plan to place rapid DNA analyzers at booking stations around the country.

The US National Institutes of Health is to review studies that have received private support for conflicts of interest, according to the New York Times.

In Science this week: the PsychENCODE Consortium reports on the molecular mechanisms of neuropsychiatric disorders, and more.